down arrow

Pyxis Oncology, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US7473241013
USD
4.22
-0.1 (-2.31%)

Dec 05

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

4.184.42

52 Week

0.835.55
Valuation
Technical
Day's Volume

CASH

418.07 k

Shareholding (Mar 2025)

FII

3.98%

Held by 36 FIIs

DII

68.83%

Held by 17 DIIs

Promoter

14.39%

How big is Pyxis Oncology, Inc.?

22-Jun-2025

As of Jun 18, Pyxis Oncology, Inc. has a market capitalization of 73.72 million and reported net sales of 0.00 million with a net profit of -95.23 million for the latest four quarters. The balance sheet shows shareholder's funds of 120.75 million and total assets of 157.18 million.

As of Jun 18, Pyxis Oncology, Inc. has a market capitalization of 73.72 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -95.23 million during the same period.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 120.75 million and total assets of 157.18 million.

Read More

What does Pyxis Oncology, Inc. do?

22-Jun-2025

Pyxis Oncology, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $21 million and a market cap of $73.72 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -72.03%.

Overview:<BR>Pyxis Oncology, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -21 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 73.72 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.02 <BR>Return on Equity: -72.03% <BR>Price to Book: 0.71 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Pyxis Oncology, Inc. overvalued or undervalued?

20-Sep-2025

As of August 14, 2025, Pyxis Oncology, Inc. is considered risky and overvalued despite a recent 87.1% one-month return, with concerning long-term performance reflected in a -36.61% one-year return compared to the S&P 500's 17.14%.

As of 14 August 2025, the valuation grade for Pyxis Oncology, Inc. has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued based on its current metrics, particularly with a Price to Book Value of 0.81, an EV to EBIT of 0.25, and an EV to EBITDA of 0.26. In comparison to peers, Eton Pharmaceuticals, Inc. has a significantly higher EV to EBITDA of 187.8463, while Ocugen, Inc. shows an EV to EBITDA of -6.1838, highlighting Pyxis's relative valuation challenges.<BR><BR>Despite a strong recent performance with a 1-month return of 87.1% compared to the S&P 500's 2.33%, the long-term outlook remains concerning, as the 1-year return of -36.61% starkly contrasts with the S&P 500's 17.14%. This suggests that while short-term gains may attract attention, the overall valuation metrics indicate that Pyxis Oncology, Inc. is currently overvalued.

Read More

Is Pyxis Oncology, Inc. technically bullish or bearish?

20-Sep-2025

As of September 5, 2025, Pyxis Oncology, Inc. shows a neutral trend with mixed indicators, having recently shifted from mildly bullish to sideways, while significantly outperforming the S&P 500 in the short term but underperforming over the past year, suggesting a cautious approach.

As of 5 September 2025, the technical trend for Pyxis Oncology, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed indicators influencing this position. The weekly MACD is bullish, while the RSI is bearish, indicating some divergence in momentum. Moving averages on the daily timeframe remain bullish, but the monthly KST is bearish, suggesting caution. Additionally, the Bollinger Bands show a bullish signal weekly but a mildly bearish signal monthly. <BR><BR>In terms of performance, the stock has significantly outperformed the S&P 500 over the past week and month, with returns of 24.73% and 87.1% respectively, but has underperformed over the past year with a return of -36.61% compared to the S&P 500's 17.14%. Overall, the mixed signals and recent trend change suggest a cautious approach.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Negative results in Jun 25

  • NET SALES(HY) At USD 2.82 MM has Grown at -82.53%
  • NET PROFIT(HY) At USD -39.51 MM has Grown at -92.21%
  • ROCE(HY) Lowest at -74.8%
2

Risky - Negative EBITDA

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 122 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.01

stock-summary
Return on Equity

-85.94%

stock-summary
Price to Book

1.39

Revenue and Profits:
Net Sales:
3 Million
(Quarterly Results - Jun 2025)
Net Profit:
-18 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
120.94%
0%
120.94%
6 Months
240.32%
0%
240.32%
1 Year
148.24%
0%
148.24%
2 Years
157.32%
0%
157.32%
3 Years
227.13%
0%
227.13%
4 Years
-65.38%
0%
-65.38%
5 Years
0%
0%
0.0%

Pyxis Oncology, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Pyxis Oncology, Inc. technically bullish or bearish?

As of 5 September 2025, the technical trend for Pyxis Oncology, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed indicators influencing this position. The weekly MACD is bullish, while the RSI is bearish, indicating some divergence in momentum. Moving averages on the daily timeframe remain bullish, but the monthly KST is bearish, suggesting caution. Additionally, the Bollinger Bands show a bullish signal weekly but a mildly bearish signal monthly. In terms of performance, the stock has significantly outperformed the S&P 500 over the past week and month, with returns of 24.73% and 87.1% respectively, but has underperformed over the past year with a return of -36.61% compared to the S&P 500's 17.14%. Overall, the mixed signals and recent trend change suggest a cautious approach....

Read More

Is Pyxis Oncology, Inc. overvalued or undervalued?

As of 14 August 2025, the valuation grade for Pyxis Oncology, Inc. has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued based on its current metrics, particularly with a Price to Book Value of 0.81, an EV to EBIT of 0.25, and an EV to EBITDA of 0.26. In comparison to peers, Eton Pharmaceuticals, Inc. has a significantly higher EV to EBITDA of 187.8463, while Ocugen, Inc. shows an EV to EBITDA of -6.1838, highlighting Pyxis's relative valuation challenges. Despite a strong recent performance with a 1-month return of 87.1% compared to the S&P 500's 2.33%, the long-term outlook remains concerning, as the 1-year return of -36.61% starkly contrasts with the S&P 500's 17.14%. This suggests that while short-term gains may attract attention, the overall valuation metrics indicate that Pyxis Oncology, Inc. is currently overva...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
30.19%
EBIT Growth (5y)
-342.88%
EBIT to Interest (avg)
-65.66
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.02
Sales to Capital Employed (avg)
0.09
Tax Ratio
2.22%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
72.55%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.81
EV to EBIT
0.25
EV to EBITDA
0.26
EV to Capital Employed
9.49
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
3742.04%
ROE (Latest)
-72.03%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 23 Schemes (12.81%)

Foreign Institutions

Held by 36 Foreign Institutions (3.98%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -6.36% vs -8.81% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.20",
          "val2": "-19.40",
          "chgp": "1.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-18.40",
          "val2": "-17.30",
          "chgp": "-6.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-7,003.50%",
          "val2": "0.00%",
          "chgp": "-700.35%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -4.74% vs 38.86% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "16.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-65.50",
          "val2": "-80.20",
          "chgp": "18.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-21.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-77.30",
          "val2": "-73.80",
          "chgp": "-4.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4,242.30%",
          "val2": "0.00%",
          "chgp": "-424.23%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
2.80
0.00
Operating Profit (PBDIT) excl Other Income
-19.20
-19.40
1.03%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-18.40
-17.30
-6.36%
Operating Profit Margin (Excl OI)
-7,003.50%
0.00%
-700.35%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -6.36% vs -8.81% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
16.10
0.00
Operating Profit (PBDIT) excl Other Income
-65.50
-80.20
18.33%
Interest
0.00
0.00
Exceptional Items
-21.00
0.00
Consolidate Net Profit
-77.30
-73.80
-4.74%
Operating Profit Margin (Excl OI)
-4,242.30%
0.00%
-424.23%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -4.74% vs 38.86% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Pyxis Oncology, Inc. stock-summary
stock-summary
Pyxis Oncology, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."